Now in its fourth edition, the conference focuses on scientific and clinical advances in the application of cell therapies in regenerative medicine and CAR-T therapies in the field of onco-haematology for immune disorders (rheumatology) and oncology, with a view to the future.
The conference is structured around two scientific sessions:
- The first session will focus on advances in bioengineering with mesenchymal stem cells and the clinical applications of biocompatible and bioresorbable scaffolds for regenerative therapy of bone/cartilage, skin and cornea.
- The second session will be dedicated to “CAR-T” (Chimeric Antigen Receptor T cell) therapy, which is an advanced form of “immunotherapy” based on the use of engineered T lymphocytes (from the patient) expressing a specific chimeric receptor directed against a tumour antigen.
The results of the efficacy and safety of CAR-T therapy against certain forms of “aggressive” leukaemia and lymphoma will be presented and discussed, such as: acute lymphoblastic leukaemia (ALL), diffuse large B-cell non-Hodgkin lymphoma (DLBCL), Primary Mediastinal Non-Hodgkin's Lymphoma (PML), Mantle Cell Lymphoma (MCL), Follicular Lymphoma and Multiple Myeloma.
Early and late complications will also be discussed, with particular reference to infectious complications.
Translated with DeepL.com (free version)